Ironwood Pharma (IRWD) Misses Q4 EPS by 4c, Misses on Revenue; Offers FY25 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
February 27, 2025 7:00 AM ESTAnnounced positive data from open-label extension study demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time
Initiated rolling NDA submission; on track to be completed in Q3 2025
LINZESS® (Iinaclotide) EUTRx prescription demand growth of 11% for full-year 2024 year-over-year
2024 Ironwood revenue of $351 million, GAAP net income of $2 million and adjusted EBITDA of $101 million
BOSTON--(BUSINESS... More



